Open AccessDeferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with -thalassemia major
Author(s) -
Dudley J. Pennell,
John B. Porter,
Maria Domenica Cappellini,
Lee Lee Chan,
Amal ElBeshlawy,
Yeşim Aydınok,
Hishamshah Mohd Ibrahim,
Chi Kong Li,
Vip Viprakasit,
Mohsen Saleh Elalfy,
Antonis Kattamis,
Gillian Smith,
Dany Habr,
Gabor Domokos,
Bernard Roubert,
Ali T. Taher
Publication year - 2012
Publication title -
haematologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.782
H-Index - 142
eISSN - 1592-8721
pISSN - 0390-6078
DOI - 10.3324/haematol.2011.049957
Subject(s) - deferasirox , medicine , ejection fraction , creatinine , thalassemia , adverse effect , beta thalassemia , cardiology , heart failure
Prospective data on cardiac iron removal are limited beyond one year and longer-term studies are, therefore, important.